Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2110877rdf:typepubmed:Citationlld:pubmed
pubmed-article:2110877lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:2110877lifeskim:mentionsumls-concept:C0018026lld:lifeskim
pubmed-article:2110877lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:2110877lifeskim:mentionsumls-concept:C1522577lld:lifeskim
pubmed-article:2110877lifeskim:mentionsumls-concept:C1518896lld:lifeskim
pubmed-article:2110877pubmed:issue2lld:pubmed
pubmed-article:2110877pubmed:dateCreated1990-6-20lld:pubmed
pubmed-article:2110877pubmed:abstractTextThe forty participants in a double blind controlled trial of parenteral methotrexate or gold for RA were followed up two years later. Fifty percent had remained on the original medication, 13/20 on MTX and 7/20 on gold. Only 5 and 3 of them respectively had no active joint swelling. No major differences between the two groups were seen.lld:pubmed
pubmed-article:2110877pubmed:languageenglld:pubmed
pubmed-article:2110877pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2110877pubmed:citationSubsetIMlld:pubmed
pubmed-article:2110877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2110877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2110877pubmed:statusMEDLINElld:pubmed
pubmed-article:2110877pubmed:issn0392-856Xlld:pubmed
pubmed-article:2110877pubmed:authorpubmed-author:RussellA SASlld:pubmed
pubmed-article:2110877pubmed:authorpubmed-author:Suarez-Almazo...lld:pubmed
pubmed-article:2110877pubmed:issnTypePrintlld:pubmed
pubmed-article:2110877pubmed:volume8lld:pubmed
pubmed-article:2110877pubmed:ownerNLMlld:pubmed
pubmed-article:2110877pubmed:authorsCompleteYlld:pubmed
pubmed-article:2110877pubmed:pagination163-6lld:pubmed
pubmed-article:2110877pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2110877pubmed:meshHeadingpubmed-meshheading:2110877-...lld:pubmed
pubmed-article:2110877pubmed:meshHeadingpubmed-meshheading:2110877-...lld:pubmed
pubmed-article:2110877pubmed:meshHeadingpubmed-meshheading:2110877-...lld:pubmed
pubmed-article:2110877pubmed:meshHeadingpubmed-meshheading:2110877-...lld:pubmed
pubmed-article:2110877pubmed:meshHeadingpubmed-meshheading:2110877-...lld:pubmed
pubmed-article:2110877pubmed:meshHeadingpubmed-meshheading:2110877-...lld:pubmed
pubmed-article:2110877pubmed:meshHeadingpubmed-meshheading:2110877-...lld:pubmed
pubmed-article:2110877pubmed:meshHeadingpubmed-meshheading:2110877-...lld:pubmed
pubmed-article:2110877pubmed:meshHeadingpubmed-meshheading:2110877-...lld:pubmed
pubmed-article:2110877pubmed:articleTitleParenteral methotrexate or gold for rheumatoid arthritis: a follow up.lld:pubmed
pubmed-article:2110877pubmed:affiliationDepartment of Medicine, University of Alberta, Canada.lld:pubmed
pubmed-article:2110877pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2110877pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2110877lld:pubmed